A Look At U.S. Physical Therapy (USPH) Valuation After 2025 Results And New Hospital Affiliations

U.S. Physical Therapy (USPH) is back in focus after reporting 2025 results that included higher net revenue and adjusted EBITDA, along with two new hospital affiliations that are expected to expand its clinic footprint from mid 2026.

See our latest analysis for U.S. Physical Therapy.

At a share price of US$83.25, U.S. Physical Therapy has posted a 10.4% 3 month share price return and a 7.3% 1 year total shareholder return, with longer term total returns still in decline. This suggests recent earnings, the dividend increase and new hospital alliances are improving sentiment after a weaker multi year stretch.

If this earnings update has you thinking about where healthcare exposure could come from next, take a look at our screener of 31 healthcare AI stocks as a starting shortlist.

So with USPH trading at US$83.25 after a mixed earnings picture, a richer dividend and new hospital alliances on the way, is this still an underappreciated healthcare compounder or has the market already priced in the next leg of growth?

Most Popular Narrative: 22.1% Undervalued

At $83.25, the most followed narrative suggests U.S. Physical Therapy trades at a discount to its implied fair value of about $106.83, anchored on earnings and margin expansion over time.

Expansion into employer health services and potential regulatory benefits support diversified income streams and further improve future profitability.

Acquisition of high-performing clinics, especially in higher reimbursement geographies like New York, and a robust de novo and acquisition pipeline, provide further expansion of the patient base, enable contract pricing leverage, and increase average net rates, all supporting margin and earnings growth.

Read the complete narrative.

Curious what sits behind that higher fair value tag? The narrative leans on compounding earnings, firmer margins, and a future valuation multiple that assumes a lot has to go right. The exact growth and profitability hurdles are clear in the full model, but not obvious from the headline figures you usually see.

Result: Fair Value of $106.83 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you also need to weigh ongoing reimbursement pressure and tight clinician staffing, as these factors could cap margins and challenge the upbeat earnings narrative.

Find out about the key risks to this U.S. Physical Therapy narrative.

Another View: High Price Tag On Current Earnings

That 22.1% undervaluation story sits alongside a very different message from the P/E. At $83.25, U.S. Physical Therapy trades on a 58.4x P/E, versus 23.7x for the US Healthcare industry and 15.3x for peers, and above a fair ratio of 27.1x. That gap points to clear valuation risk if growth or margins fall short. Which signal do you think deserves more weight?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and concern feels familiar, it is a good moment to look under the hood yourself and move quickly to form your own view. You can see how the positives stack up against the watchpoints in our summary of 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

Before you move on, consider expanding your watchlist by scanning a few focused stock ideas that might fit different roles in a portfolio.

• Review resilient cash generators using our screen of 49 high quality undervalued stocks, which combines quality fundamentals with prices that appear out of sync with underlying metrics.
• Explore a curated set of 15 dividend fortresses that may appeal to investors who value regular cash returns.
• Assess your downside protection by reviewing 75 resilient stocks with low risk scores, which scores well on financial stability and risk checks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com